The Rationale For Genetically Profiling AML Patients

Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses The Rationale For Genetically Profiling AML Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com